JPMorgan Chase & Co. Has $2.61 Million Stock Holdings in Artivion, Inc. (NYSE:AORT)

JPMorgan Chase & Co. raised its stake in Artivion, Inc. (NYSE:AORT) by 394.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,903 shares of the company’s stock after buying an additional 78,120 shares during the period. JPMorgan Chase & Co. owned 0.23% of Artivion worth $2,606,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Quarry LP raised its holdings in Artivion by 210.8% in the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after buying an additional 820 shares during the last quarter. RiverPark Advisors LLC raised its stake in shares of Artivion by 151.6% during the third quarter. RiverPark Advisors LLC now owns 5,387 shares of the company’s stock valued at $143,000 after acquiring an additional 3,246 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Artivion during the second quarter worth $253,000. XTX Topco Ltd bought a new stake in shares of Artivion in the second quarter worth $331,000. Finally, Marshall Wace LLP acquired a new stake in Artivion in the second quarter valued at $366,000. Institutional investors own 86.37% of the company’s stock.

Insider Transactions at Artivion

In other news, CAO Amy Horton sold 4,329 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $29.66, for a total transaction of $128,398.14. Following the completion of the sale, the chief accounting officer now owns 135,660 shares in the company, valued at $4,023,675.60. The trade was a 3.09 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Andrew M. Green sold 7,618 shares of Artivion stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total transaction of $228,540.00. Following the completion of the sale, the vice president now directly owns 33,503 shares of the company’s stock, valued at approximately $1,005,090. The trade was a 18.53 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 20,017 shares of company stock valued at $600,007 in the last quarter. 8.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages have commented on AORT. Oppenheimer lifted their target price on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Artivion in a research note on Monday, December 9th. Finally, JMP Securities reissued a “market outperform” rating and set a $33.00 target price on shares of Artivion in a research report on Tuesday, December 10th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $31.80.

Artivion Stock Down 1.5 %

Shares of NYSE:AORT opened at $30.76 on Tuesday. The business’s 50-day moving average is $28.85 and its 200-day moving average is $27.19. Artivion, Inc. has a 1 year low of $16.48 and a 1 year high of $32.33. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -1,537.95 and a beta of 1.74. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.